- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
Ethnicity and Atopic Dermatitis
Author(s):
In this video, Ama Alexis, MD, tells us what we have to look forward to at the ACAAI conference this week.
Ama Alexis, MD, an allergist-immunologist in private and academic practice in New York, New York, highlights what makes the American College of Allergy, Asthma, and Immunology (ACAAI) conference different, what her presentation is going to be about, and what she's looking forward to over this weekend.
The ACAAI conference will be happening November 4 to 8 in New Orleans, Louisiana. Be sure to check out continued coverage of the event on our website.
Video Player is loading.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes
Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11
The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients
Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis
The Impact of Atopic Dermatitis on Quality of Life and the Role of New Therapies
Balancing Safety and Progress in Pediatric AD
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Related Content
